|Randy Mills in San Diego, Union-Tribune photo by K.C. Alfred|
"We do not have enough industry pull for our technology….We don't have enough buyers for our intellectual property."The article continued,
“Stem cell therapies are still considered too risky by most companies, Mills said.”
About 70 persons attended the meeting, according to Fikes. That is about 10 times the size of the audience at most meetings of the governing board of the California Institute for Regenerative Medicine or CIRM, as the San Francisco agency is formally known.
Many in the audience were there to pitch for Parkinson’s. Fikes wrote,
“Patient advocate Sherrie Gould asked Mills to support funding a potential Parkinsons' disease therapy being developed by a coalition of scientists, doctors and Parkinson's patients called Summit4StemCell. Dozens of coalition supporters attended the meeting.
“The group seeks to grow replacement brain cells to relieve symptoms of the movement disorder, derived from the patient's own skin cells. It's affiliated with the Parkinson's Association of San Diego.”Fikes continued,
|David Higgins, Linked In photo|
“We are ready, the patients are ready, the cells are ready,’ Gould said. ‘Time is running out for these patients.’"The 29-member CIRM board has a Parkinson’s patient advocate as a member, David Higgins of San Diego, who is a former president of the Parkinson’s Association, according to CIRM.